Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024)
Fulcrum Therapeutics' (FULC) quarterly EBT Margin came in at 50.27% in Q2 2024, up 353345.0% year-on-year from N/an in Q3 2023, and up 101.02% on a QoQ basis from 4949.03% in Q4 2023.
Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has 5 years of EBT Margin data on file, last reported at 50.27% in Q2 2024.
- On a quarterly basis, EBT Margin rose 353345.0% year-over-year to 50.27% in Q2 2024; TTM through Jun 2025 was 210.63%, a 7785.0% decrease from a year earlier, with the FY2024 full-year figure at 91.73%, up 969387.0% from the prior year.
- EBT Margin for Q2 2024 stood at 50.27%, up from 4949.03% in the prior quarter.
- Over the last five years, EBT Margin for FULC reached as high as 50.27% in Q2 2024 and fell as low as 28095.77% in Q4 2022.
- Historically, EBT Margin has averaged 4342.53% across 5 years, with a median of 2120.94% in 2020.
- Across the five-year window, EBT Margin tumbled 2708843 bps in 2022 and soared 2314673 bps in 2023, its largest moves.
- Year by year, EBT Margin stood at 421.8% in 2020, then plunged by 139 bps to 1007.34% in 2021, then tumbled by 2689 bps to 28095.77% in 2022, then jumped by 82 bps to 4949.03% in 2023, then surged by 101 bps to 50.27% in 2024.
- Per Business Quant data, the three most recent EBT Margin figures were 50.27% in Q2 2024, 4949.03% in Q4 2023, and 5304.35% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 33.74% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fulcrum Therapeutics | 285.43 Mn | 285.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 50.27% |
| Dec 31, 2023 | -4,949.03% |
| Sep 30, 2023 | -5,304.35% |
| Jun 30, 2023 | -3,483.18% |
| Mar 31, 2023 | -10,346.78% |
| Dec 31, 2022 | -28,095.77% |
| Sep 30, 2022 | -2,289.43% |
| Jun 30, 2022 | -1,883.21% |
| Mar 31, 2022 | -3,626.42% |
| Dec 31, 2021 | -1,007.34% |
| Sep 30, 2021 | -1,954.77% |
| Jun 30, 2021 | -867.11% |
| Mar 31, 2021 | -477.82% |
| Dec 31, 2020 | -421.80% |
| Sep 30, 2020 | -2,120.94% |
| Jun 30, 2020 | -1,707.39% |
| Mar 31, 2020 | -5,337.87% |